

Cover Story
Real-world Evidence
Routine screening procedures for breast, colon, and cervical cancers in the first half of 2021 have failed to recover, falling by about a third below historical baselines, even as Americans are resuming normal activities.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- ODAC Confidential: The seven deadly sins sponsors commit again and again at FDA presentations
- C. David Allis, pioneer of chromatin biology and epigenetics, dies at 71
- Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization”
- NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research
- Epigeneticists may be looking for epigenome-disease associations in the wrong place
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission